Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial

SPLASH (NCT04647526) is a multicenter phase III trial evaluating the efficacy and safety of [ Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC). This study leveraged a lead-in phase to assess tissue dosimetry and evaluate preliminary safety and efficacy, pr...

Full description

Bibliographic Details

Published in:	Frontiers in oncology Vol. 14; p. 1483953
Main Authors:	Hansen, Aaron R., Probst, Stephan, Beauregard, Jean-Mathieu, Viglianti, Benjamin L., Michalski, Jeff M., Tagawa, Scott T., Sartor, Oliver, Tutrone, Ronald F., Oz, Orhan K., Courtney, Kevin D., Delpassand, Ebrahim S., Nordquist, Luke T., Osman, Medhat M., Chi, Kim N., Sparks, Richard, George, Noble, Hawley, Sara M., Wu, Wenting, Jensen, Jessica D., Fleshner, Neil E.
Format:	Journal Article
Language:	English
Published:	Switzerland Frontiers Media S.A 07.01.2025
Subjects:	castration resistant prostate cancer dosimetry Oncology PNT2002 PSMA radioligand therapy PSMA dosimetry PNT2002 castration resistant prostate cancer radioligand therapy
ISSN:	2234-943X, 2234-943X
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!